In recent clinical trials, treatment with an ASO drug candidate, eluforsen, which specifically targets the F508del-CFTR mutation, resulted in improved chloride and sodium transport, as measured by a nasal potential difference (NPD), in CF patients when delivered via bilateral intranasal administration three times a week for four weeks (64). The gene discussed is CFTR; the disease is cystic fibrosis.